AdAlta (ASX:1AD) Shares Buyback Ratio %: -177.78 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is AdAlta Shares Buyback Ratio %?

AdAlta ASX:1AD Shares Buyback Ratio % is -177.78 as of Aug. 27, 2026. The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. AdAlta's current shares buyback ratio was -177.78%.

AdAlta Shares Buyback Ratio % Related Terms

AdAlta Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for AdAlta's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AdAlta Shares Buyback Ratio % Chart

AdAlta Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.90 -16.71 -62.44 -51.09 -177.78

AdAlta Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.28 -6.02 -42.51 -114.25 -29.65

AdAlta Shares Buyback Ratio % Calculation

AdAlta's Shares Buyback Ratio for the fiscal year that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Jun. 2025 )
=(1071.316 - 2975.919) / 1071.316
=-177.78%

AdAlta's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(2295.269 - 2975.919) / 2295.269
=-29.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -177.78 mean?
AdAlta (ASX:1AD) has a Shares Buyback Ratio % of -177.78 as of Aug. 27, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on AdAlta and its competitors.
Is AdAlta's Shares Buyback Ratio % too high?
AdAlta's current Shares Buyback Ratio % is -177.78.
How does AdAlta's Shares Buyback Ratio % compare to VRTX and REGN?
AdAlta's Shares Buyback Ratio % of -177.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on AdAlta and its competitors. AdAlta's current Shares Buyback Ratio % is -177.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AdAlta stock overvalued right now?
AdAlta (ASX:1AD) has a current Shares Buyback Ratio % of -177.78. The current Shares Buyback Ratio % is -177.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For AdAlta (ASX:1AD), the current Shares Buyback Ratio % is -177.78 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AdAlta Business Description

Address 697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.